Chronic viral hepatitis B
Conditions
Interventions
PegIFNa-2b treatment group:NA
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1.Voluntary enrollment, able to understand and sign the informed consent form; 2.At the time of signing the informed consent form, the age should be between 18 and 65 years old (including the boundary value), and there is no gender restriction. 3.HBsAg was positive during screening, and the history of HBsAg positivity was at least 6 months or there was other evidence suggesting CHB; 4.Interferon and other immunomodulators have not been used within 6 months prior to treatment; 5.The subjects denied pregnancy (women of childbearing age) and agreed to take effective contraceptive measures during the study period.
Exclusion criteria
Exclusion criteria: 1.Autoimmune liver disease, alcoholic hepatitis, drug-induced hepatitis, other viral hepatitis, moderate and severe steatohepatitis, decompensated liver disease and hepatocellular carcinoma; 2.There are other important organ diseases such as severe heart disease, uncontrolled diabetes, hypertension, thyroid disease, retinopathy, psychosis, autoimmune disease and epilepsy; 3.Autoimmune diseases, including psoriasis and systemic lupus erythematosus; 4.Confirmed or suspected liver cancer and other malignant tumors; 5.Unrequited alcoholics or drug addicts; 6.lactating women and those who plan to be pregnant within 2 years; 7.After organ transplantation or those who are ready for organ transplantation; 8.Those who are receiving immunosuppressant treatment; 9.Serum alanine aminotransferase level >10×ULN, total bilirubin level >2×ULN (anti-inflammatory and liver-protecting drugs should be used for at least 2 weeks); 10.Neutrophil count < 1.5×10^9/L and/or platelet count < 50× 10^9/L; 11.People who are allergic to research drugs (including PegIFNa-2b and NAs) or any of its components; 12.There are any contraindications in the instructions for drugs used in research; 13.Current infection with chronic infectious diseases such as hepatitis A, hepatitis C, hepatitis D, hepatitis E and HIV; 14.Other circumstances that the researcher thinks are not suitable for the group.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HBV RNA;T cell count;HBV-DNA quantification;HBsAg quantification; | — |
Countries
China
Contacts
Public ContactLi Hong
West China Hospital of Sichuan University
Outcome results
None listed